Drug Profile


Alternative Names: AFP 168; DE-085; DE-118; MK-2452; Saflutan; Taflotan; Tapros; Tapros mini ophthalmic solution 0.0015%; Tapros ophthalmic solution 0.0015%; Zioptan

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Santen Pharmaceutical
  • Developer Merck & Co; Santen Pharmaceutical
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Apr 2016 Preservative-free formulation launched for Glaucoma and Ocular hypertension in Singapore (Santen pipeline, July 2016)
  • 01 Mar 2016 Launched for Ocular hypertension and Glaucoma in China (Ophthalmic) (Santen pipeline, July 2016)
  • 29 Feb 2016 Santen Oy initiates enrolment in a phase I trial for Glaucoma and Ocular hypertension (In children, In adolescent) in Hungary (EudraCT2013-004302-26)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top